India Arms Of Drug MNCs To See Some Cost-Cutting Benefit – Novartis India Head
This article was originally published in PharmAsia News
Executive Summary
Indian subsidiaries of multinational pharmaceutical firms are feeling the pains of their parents in trying to weather the global financial crisis. Several are laying off Indian employees to reduce costs, and an expectation that layoffs abroad would lead to job safety in India has not been realized. Fortunately for subsidiaries in China and India, they are relatively small compared with the MNC, so the cost cuts are not expected to be as deep. The head of Novartis AG's Indian arm said the cost-cutting moves by MNCs is expected to lead them into more outsourcing, benefiting countries such as India. (Click here for more
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.